ResearcherThe University of MelbourneActive in the last 2 years

Kevin Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6712-126X; OpenAlex author ID A5068694615. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 2

Neoadjuvant Pembrolizumab Enables Successful Downstaging and Resection of Borderline Resectable MSI-H/dMMR Pancreatic Ductal Adenocarcinoma: A Case Report and … Co-author DOI 10.1007/s12029-025-01237-5 ↗
Lymph node yield as a measure of pancreatic cancer surgery quality. Co-author DOI 10.1016/j.sipas.2022.100103 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Vijayaragavan Muralidharan · 1 shared paper, 2025 · strength 0.30
- Paper Neoadjuvant Pembrolizumab Enables Successful Downstaging and Resection of Borderline Resectable MSI-H/dMMR Pancreatic D… DOI 10.1007/s12029-025-01237-5 ↗
Prasad D. Cooray · 1 shared paper, 2025 · strength 0.30
- Paper Neoadjuvant Pembrolizumab Enables Successful Downstaging and Resection of Borderline Resectable MSI-H/dMMR Pancreatic D… DOI 10.1007/s12029-025-01237-5 ↗
Joseph Blansfield · 1 shared paper, 2022 · strength 0.19
- Paper Lymph node yield as a measure of pancreatic cancer surgery quality. DOI 10.1016/j.sipas.2022.100103 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.